AMANTAAmanta Healthcare Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassWatch
Market Cap₹385 Cr
Primary DriverGovernance
Flagium AI Risk Score
Early signs of stress detected. Not yet widespread, but initial deterioration is visible.
25 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in governance. This suggests the risk profile is currently stabilizing. Risk levels are improving.

65.7th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹115.32▼4.86%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Stability Adjustment
+25.0 pts
Final Composite Risk25 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 25 over 12 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
  • Low Interest Coverage
What to Watch Next Quarter
  • Working capital efficiency
  • Inventory turnover
  • Operating profit margins

Active Risk Objects (3)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 1 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 349.8%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ2 FY2026
Inventory growth (0.3%) significantly outpaced revenue growth (-75.6%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 3 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ3 FY2026
AMANTA: Low Interest Coverage Ratio of 2.25x in FY2026 Q3 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)4.097.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+41.0+47.0📈 CRITICAL
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹115.32(-4.86%)
1M Divergence-14.32%
1 Week-13.46%
1 Month-12.06%
6 Months+13.26%
1 YearN/A
2 Year-15.43%
3 Year-15.43%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The risk profile is Early Signals and currently improving. Recent structural triggers in governance suggest a building pressure on the underlying framework. Material forensic traces are visible in structural transparency and audit trails, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.

AMANTA • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.8%
Trend QualityEarly Base
Phase Progression
Phase Progression Score22.5%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing8%
CoinTree Momentum
Composite Z-Score-0.1739σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#1351 of 2716
Top 49.74% in momentum strength
Timeframe Sparklines
1W-13.5%
1M-12.1%
6M+13.3%
Weinstein Indicators
150 DMA₹113.21
200 DMA₹N/A
150 DMA Slope-0.4920%Declining
Relative Strength+16.86%Leading
Relative Turnover (RTR)1.0000
ParticipationNeutral

PEER COMPARISON

Ranked comparison against sector peers

This company shows higher risk compared to the Sector Mean (19).
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AMANTAAmanta Healthcare Limited
25 Risk
Sector %ile66th
Delta-5
Active Flags3
Accel+0
Governance

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

BALAXIBALAXI PHARMACEUTICALS LIMITED
45 Risk
Sector %ile96th
Delta+10
Active Flags40
Accel+1
Balance Sheet Stress

Moderate Deterioration

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20262911548234